

CHAMPION-AF

Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation

OBJECTIVE: To investigate whether device-based left atrial appendage closure is noninferior to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in preventing major cardiovascular (CV) events, or superior in reducing non-procedure-related bleeding, in patients with atrial fibrillation who are eligible for anticoagulation

STUDY DESIGN: Prospective, international, randomized trial, N=3,000

CONCLUSIONS: Compared to NOAC therapy, device-based left atrial appendage closure was noninferior in preventing death from CV causes, stroke, or systemic embolism and superior for non-procedure-related bleeding at 3 years.



American
Heart
Association.